由于C1抑制剂缺乏而导致的遗传性血管:当前的治疗方法
Giulia Costanzo1, Giada Sambugaro, Davide Firinu
1University of Cagliari: università degli studi di Cagliari, Monserrato, CA, Italy.
Current opinion in allergy and clinical immunology
|October 16, 2024
概括
新的遗传性血管 (HAE) 治疗提供了改善的自我管理和预防. 在HAE病理生理学的进步使个性化护理能够最大限度地减少攻击并提高患者的生活质量.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 遗传性血管 (HAE) 从历史上看,由于副作用和管理挑战,治疗选择有限.
- 了解HAE病理生理学推动了新型治疗策略的开发.
研究的目的:
- 为HAE.提供已批准的药物的全面审查.
- 讨论HAE治疗的演变,包括自我治疗和预防.
主要方法:
- 对已批准的HAE药物进行文献审查.
- 分析HAE病理生理学和治疗开发的最新进展.
主要成果:
- 创新药物现在允许对HAE进行自给自取的按需治疗和预防.
- 新疗法促进了个性化的行动计划,重点是减少发作和满足患者需求.
结论:
- HAE是一种罕见的遗传性疾病,由于不可预测的发作,严重影响生活质量.
- HAE研究的进步使得最佳的攻击管理和个性化的治疗方法成为可能.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
143
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
143
Antihypertensive Drugs: Direct Renin Inhibitors
505
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
505
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
490
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
490
Open Angle Glaucoma: Treatment
401
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
401
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
137
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
137


